

## PART A: Research results at the center of the therapeutic revolution



12

July

The Dependence Receptor concept: from cell biology to clinical trial

Early stage drug valuation:

## **Prof. Agnes Bernet**

Professor at University Claude Bernard Lyon 1, Co-founder and chief scientific officer at Netris pharma (Lyon, France)

Dr. Revital Rattenbach

## 21 June New innovation models for biopharmaceutical innovation: preparing the ne generation of healthcare profes

**Prof. Michel Goldman** founder and co-director of the Institute for interdisciplinary Innovation in Healthcare in Brussels (Brussels, Belgium) **Dr. Bernard Vanhove** Founder and chief operating officer at OSE Immunotherapeutics (Paris, France)

**27** Oct.

30

June

Personalized medicine as a future: the Biomarkers example

The drug development process and the role of

academic research in it

Dr. Inês Amado Project Manager, Biomarkers and compagnion tests, Aviesan (Paris, France)

## PART B: Define, mature and realize your applied research projects: valorization tools

22

Sept.

**TBC** 

TBC Nov. Why and how to move research results towards translationnal research and clinical applications

Chief Excecutive Officer of 4P Pharma (Lille, France)

BC Public/private partnerships: bringing science closer to society

Healthcare decision makers:

2018

TBC Jan. Technology/molecule development through spin-off creation: a valuable step for research results valorization

TRC Feb. academic results and clinical applications

Researchers, clinicians, compa-<br/>nies, patients associations:<br/>connecting medical science people to<br/>achieve effective clinical trials

TBC April Luxembourgish and european funding schemes supporting collaborative projects and entrepreneurship

Coordinated by Research Knowledge Transfer Office (KITS/ACTOR project) Get more details on our lectures! Sign up for the newsletter on our website! www.lih.lu

